Effects of the prostanoids on the proliferation or hypertrophy of cultured murine aortic smooth muscle cells.
Effects of the prostanoids on the growth of cultured aortic vascular smooth muscle cells (VSMCs) were examined using mice lacking prostanoid receptors. Proliferation of VSMCs was assessed by measuring [(3)H]-thymidine incorporation and the cell number, and their hypertrophy by [(14)C]-leucine incorporation and protein content. In VSMCs from wild-type mice, expressions of mRNAs for the EP(4) and TP were most abundant, followed by those for the IP, EP(3) and FP, when examined by competitive reverse transcriptase-PCR. Those for the EP(1), EP(2) and DP, however, could not be detected. AE1-329, an EP(4) agonist, and cicaprost, an IP agonist, inhibited platelet derived growth factor (PDGF)-induced proliferation of VSMCs from wild-type mice; these inhibitory effects disappeared completely in VSMCs from EP(4)(-/-) and IP(-/-) mice, respectively. In accordance with these effects, AE1-329 and cicaprost stimulated cAMP production in VSMCs from wild-type mice, which were absent in VSMCs from EP(4)(-/-) and IP(-/-) mice, respectively. Effects of PGE(2) on cell proliferation and adenylate cyclase were almost similar with those of AE1-329 in VSMCs from wild-type mice, which disappeared in VSMCs from EP(4)(-/-) mice. PGD(2) inhibited PDGF-induced proliferation of VSMCs from both wild-type and DP(-/-) mice to a similar extent. This action of PGD(2) was also observed in VSMCs from EP4(-/-) and IP(-/-) mice. In VSMCs from wild-type mice, I-BOP, a TP agonist, showed potentiation of PDGF-induced hypertrophy. I-BOP failed to show this action in VSMCs from TP(-/-) mice. The specific agonists for the EP(1), EP(2) or EP(3), and PGF(2)alpha showed little effect on the growth of VSMCs. These results show that PGE(2), PGI(2) and TXA(2) modulate PDGF-induced proliferation or hypertrophy of VSMCs via the EP(4), IP and TP, respectively, and that the inhibitory effect of PGD(2) on PDGF-induced proliferation is not mediated by the DP, EP(4) or IP.
Fujino
Takayuki
T
Department of Pharmacology, Asahikawa Medical College, Midorigaoka Higashi 2-1-1-1, Asahikawa 078-8510, Japan.
Yuhki
Koh-ichi
K
Yamada
Takehiro
T
Hara
Akiyoshi
A
Takahata
Osamu
O
Okada
Yuji
Y
Xiao
Chun-Yang
CY
Ma
Hong
H
Karibe
Hideji
H
Iwashima
Yasunori
Y
Fukuzawa
Jun
J
Hasebe
Naoyuki
N
Kikuchi
Kenjiro
K
Narumiya
Shuh
S
Ushikubi
Fumitaka
F
D000818:Animals; D001011:Aorta / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D017209:Apoptosis; D002452:Cell Count; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D006984:Hypertrophy; D007930:Leucine / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D009131:Muscle, Smooth, Vascular / Q000166:cytology* / Q000187:drug effects* / Q000473:pathology; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D015230:Prostaglandin D2 / Q000494:pharmacology / Q000502:physiology; D011453:Prostaglandins / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D011982:Receptors, Prostaglandin / Q000819:agonists* / Q000172:deficiency / Q000235:genetics; D013936:Thymidine / Q000378:metabolism
D010982:Platelet-Derived Growth Factor; D011453:Prostaglandins; D012333:RNA, Messenger; D011982:Receptors, Prostaglandin; D007930:Leucine; D015230:Prostaglandin D2; D013936:Thymidine